Oral Session 1-5B AML: Novel agents

[OS1-5B-4] Quizartinib prolongs overall survival in relapsed/refractory FLT3-ITD-mutated AML: A phase 3 RCT

Jorge E. Cortes¹, Samer Khaled², Giovanni Martinelli³, Alexander E. Perl⁴, Siddhartha Ganguly⁵, Nigel Russell⁶, Alwin Krämer⁷, Hervé Dombret⁸, Donna Hogge⁹, Brian A. Jonas¹⁰, Anskar Yu-Hung Leung¹¹, Priyanka Mehta¹², Pau Montesinos¹³, Markus Radsak¹⁴, Simona Sica¹⁵, Meena Arunachalam¹⁶, Melissa Holmes¹⁶, Ken Kobayashi¹⁶, Ruth Namuyinga¹⁶, Nanxiang Ge¹⁶, Antoine Yver¹⁶, Yufen Zhang¹⁶, Mark J. Levis¹⁷ (1.The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2.City of Hope National Medical Center, Duarte, CA, USA, 3.Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy, 4.University of Pennsylvania, Philadelphia, PA, USA, 5.The University of Kansas Health System, Kansas City, KS, USA, 6.Nottingham University Hospital, Nottingham, United Kingdom, 7.University of Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany, 8.University Paris Diderot, Paris, France, 9.Vancouver General Hospital, Vancouver, BC, Canada, 10.University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA, 11.The University of Hong Kong, Hong Kong, 12.The University of Bristol, Bristol, United Kingdom, 13.Hospital Universitari i Politècnic La Fe, València, Spain, 14.University Medical Center of Johannes Gutenberg University Mainz, 15.Università Cattolica del Sacro Cuore, Rome, Italy, 16.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 17.Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA)